Molecular profiling of pediatric and young adult colorectal cancer reveals a distinct genomic landscapes and potential therapeutic avenues

• Published in: Scientific reports Vol. 14; no. 1; pp. 13138 - 11
• Main Authors: Busico, A., Gasparini, P., Rausa, E., Cattaneo, L., Bozzi, F., Silvestri, M., Capone, I., Conca, E., Tamborini, E., Perrone, F., Vitellaro, M., Ricci, M.T., Casanova, M., Chiaravalli, S., Bergamaschi, L., Massimino, M., Milione, M., Sozzi, G., Pruneri, G., Ferrari, A., Signoroni, S.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 07.06.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 1-Phosphatidylinositol 3-kinase; 631/67/1504/1885; 631/67/2332; 631/67/69; Adenomatous polyposis coli; Adolescent; Adult; Age; AKT protein; Child; Child, Preschool; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - genetics; Copy number; DNA Copy Number Variations; Female; Genomics; Genomics - methods; Global health; High-Throughput Nucleotide Sequencing - methods; Humanities and Social Sciences; Humans; Inhibitors; Male; multidisciplinary; Mutation; Next-generation sequencing; Patients; Pediatrics; Precision medicine; Public health; Retrospective Studies; Science; Science (multidisciplinary); Wnt protein; Wnt Signaling Pathway - genetics; Young Adult; Young adults
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-64149-7

Colorectal cancer (CRC) is a global health concern, and the incidence of early onset (EO) CRC, has an upward trend. This study delves into the genomic landscape of EO-CRC, specifically focusing on pediatric (PED) and young adult (YA) patients, comparing them with adult (AD) CRC. In this retrospective monocentric investigation, we performed targeted next-generation sequencing to compare the mutational profile of 38 EO-CRCs patients (eight PED and 30 YA) to those of a ‘control group’ consisting of 56 AD-CRCs. Our findings reveal distinct molecular profiles in EO-CRC, notably in the WNT and PI3K-AKT pathways. In pediatrics, we observed a significantly higher frequency of RNF43 mutations, whereas APC mutations were more prevalent in adult cases. These observations suggest age-related differences in the activation of the WNT pathway. Pathway and copy number variation analysis reveal that AD-CRC and YA-CRC have more similarities than the pediatric patients. PED shows a peculiar profile with CDK6 amplification and the enrichment of lysine degradation pathway. These findings may open doors for personalized therapies, such as PI3K-AKT pathway inhibitors or CDK6 inhibitors for pediatric patients. Additionally, the distinct molecular signatures of EO-CRC underscore the need for age-specific treatment strategies and precision medicine. This study emphasizes the importance of comprehensive molecular investigations in EO-CRCs, which can potentially improve diagnostic accuracy, prognosis, and therapeutic decisions for these patients. Collaboration between the pediatric and adult oncology community is fundamental to improve oncological outcomes for this rare and challenging pediatric tumor.